Results 91 to 100 of about 2,116 (170)

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence. [PDF]

Dermatol Ther (Heidelb)
Silverberg JI, Irvine AD, Foley P, Del Rosso J, Puig L, Stein Gold L, Kamata M, Wollenberg A, Hong HC, Chu CY, Binamer Y, Dossenbach M, Casillas M, Gallo G, Akmaz B, Rand K, Chovatiya R.   +16 more
europepmc   +1 more source

Severe psoriasis relapse following tralokinumab therapy for atopic dermatitis. [PDF]

JAAD Case Rep
Zarabian N, Farah M, Zahn J, Friedman A.
europepmc   +1 more source

Tralokinumab w atopowym zapaleniu skóry

Atopowe zapalenie skóry (AZS) jest jedną z najczęściej występujących przewlekłych chorób zapalnych skóry na świecie, która dotyczy do 20% populacji dziecięcej i około 2–5% osób dorosłych. Spośród wielu mediatorów prozapalnych interleukina-13 (IL-13) jest
Walecka, Irena; Klinika Dermatologii, Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji, Warszawa; Klinika Dermatologii, Centrum Medyczne Kształcenia Podyplomowego, Warszawa, Czaplicka, Anna; Klinika Dermatologii, Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji, Warszawa; Klinika Dermatologii, Centrum Medyczne Kształcenia Podyplomowego, Warszawa   +1 more
core  

Correction: Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel. [PDF]

Dermatol Ther (Heidelb)
Mendes-Bastos P, Lobo I, Pires da Rosa G, Pimenta R, Gonçalo M, Delphi panel.   +5 more
europepmc   +1 more source

Efficacy of Tralokinumab in Atopic Dermatitis Patients With Prior Biologic and JAK Inhibitor Therapy. [PDF]

Int J Dermatol
Nigro A, Chennareddy S, Silva I, Kalagara R, Chennareddy S, Khattri S.   +5 more
europepmc   +1 more source

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay. [PDF]

J Eur Acad Dermatol Venereol
van der Gang LF, Zuithoff NPA, Haeck IM, Harbers VEM, Stadhouders-Keet S, Politiek K, Oosting AJ, van Lynden-van Nes AMT, Lam HY, van Tuyll van Serooskerken AM, Stewart SM, Gostynski A, Flinterman A, Velstra B, Touwslager WRH, van Erp FC, Schuttelaar MLA, de Bruin-Weller MS, de Graaf M.   +18 more
europepmc   +1 more source

Real-world effectiveness and safety of tralokinumab in moderate-to-severe atopic dermatitis with malignancy, chronic infections, and multimorbidity. [PDF]

Dermatol Ther (Heidelb)
Melgosa Ramos FJ, Mercader P, Santos Alarcón S, Dominguez Liron N, Bernabeu A, Rodriguez Serna M, Fernandez-Crehuet P, Silvestre JF.   +7 more
europepmc   +1 more source

Therapy-associated facial redness in atopic dermatitis: insights from a case series. [PDF]

An Bras Dermatol
Sabas-Ortega K, García-González S, Ara-Martín M, Morales-Moya AL, de la Fuente Meira S, Bularca E, Villagrasa-Boli P, Martinez-Lostao L, Rivera-Fuertes I, Prieto-Torres L.   +9 more
europepmc   +1 more source

Comparative efficacy of pediatric atopic dermatitis treatments: a network meta-analysis highlighting dupilumab and pimecrolimus for SCORAD and EASI improvement. [PDF]

Front Immunol
Yang L, Hu R, Wang Y, He Y.
europepmc   +1 more source

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation. [PDF]

Allergol Select
Werfel T, Heratizadeh A, Augustin M, Bangert C, Bauer A, Biedermann T, Brans R, Domröse N, Gieler U, Gießler-Fichtner O, Hamelmann E, Hampe S, Heuer R, Kahle J, Kinberger M, Koch M, Köhler M, Legat F, Nemat K, Neustädter I, Peters EMJ, Radonjic-Hoesli S, Reese I, Schmid-Grendelmeier P, Schmidt-Göhrich UK, Schmitt J, Schnopp C, Schwennesen T, Simon D, Stamos K, Termeer C, Treudler R, von Kiedrowski R, Wagner I, Waßmann-Otto A, Weckmann G, Werner RN, Wollenberg A, Worm M, Ott H.   +39 more
europepmc   +1 more source